NPH Humulin N
Selected indexed studies
- Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study. (Diabetes Obes Metab, 2023) [PMID:36708333]
- NPH insulin. (J Maine Med Assoc, 1950) [PMID:14784762]
- NPH insulin. (Can Med Assoc J, 1951) [PMID:14848784]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- NPH insulin. (1950) pubmed
- NPH insulin. (1951) pubmed
- Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. (2008) pubmed
- Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study. (2023) pubmed
- Revisiting NPH Insulin for Type 2 Diabetes: Is a Step Back the Path Forward? (2018) pubmed
- Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis. (2011) pubmed
- Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. (2004) pubmed
- A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. (2013) pubmed
- Bioequivalence of Jusline following subcutaneous administration in healthy subjects. (2008) pubmed
- Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin. (2021) pubmed